BR112021023359A2 - Inibidores de g12c de kras e usos dos mesmos - Google Patents

Inibidores de g12c de kras e usos dos mesmos

Info

Publication number
BR112021023359A2
BR112021023359A2 BR112021023359A BR112021023359A BR112021023359A2 BR 112021023359 A2 BR112021023359 A2 BR 112021023359A2 BR 112021023359 A BR112021023359 A BR 112021023359A BR 112021023359 A BR112021023359 A BR 112021023359A BR 112021023359 A2 BR112021023359 A2 BR 112021023359A2
Authority
BR
Brazil
Prior art keywords
kras
inhibitors
mutation
compounds
methods
Prior art date
Application number
BR112021023359A
Other languages
English (en)
Inventor
M O'boyle Brendan
M Stoltz Brian
M Reeves Corey
Dennis Slamon
A Hilf Justin
S Mcdermott Martina
D Bartberger Michael
A O'brien Neil
C Loson Oliver
E Rose Tristin
Original Assignee
1200 Pharma Llc
California Inst Of Techn
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1200 Pharma Llc, California Inst Of Techn, Univ California filed Critical 1200 Pharma Llc
Publication of BR112021023359A2 publication Critical patent/BR112021023359A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

inibidores de g12c de kras e usos dos mesmos. a invenção se refere a compostos da fórmula i, e sais farmaceuticamente aceitáveis dos mesmos, e métodos para fabricar e usar os mesmos. os compostos da invenção são eficazes em inibir a proteína kras com uma mutação g12c e são adequados para uso em métodos para tratar cânceres mediados, inteiramente ou em parte, por mutação g12c de kras.
BR112021023359A 2019-05-20 2020-05-20 Inibidores de g12c de kras e usos dos mesmos BR112021023359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850289P 2019-05-20 2019-05-20
PCT/US2020/033816 WO2020236940A1 (en) 2019-05-20 2020-05-20 Kras g12c inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112021023359A2 true BR112021023359A2 (pt) 2022-02-01

Family

ID=73458223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023359A BR112021023359A2 (pt) 2019-05-20 2020-05-20 Inibidores de g12c de kras e usos dos mesmos

Country Status (12)

Country Link
US (1) US20220227738A1 (pt)
EP (1) EP3972978A4 (pt)
JP (1) JP2022533398A (pt)
KR (1) KR20220038289A (pt)
CN (1) CN114096544A (pt)
AU (1) AU2020279253A1 (pt)
BR (1) BR112021023359A2 (pt)
CA (1) CA3141604A1 (pt)
IL (1) IL288200A (pt)
MX (1) MX2021014177A (pt)
SG (1) SG11202112790SA (pt)
WO (1) WO2020236940A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
KR20220071193A (ko) 2019-08-29 2022-05-31 미라티 테라퓨틱스, 인크. Kras g12d 억제제
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
CN114630832A (zh) * 2019-11-15 2022-06-14 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.
CN113087700B (zh) * 2020-01-08 2023-03-14 苏州亚盛药业有限公司 螺环四氢喹唑啉
US20230212164A1 (en) 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022040469A1 (en) * 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN114685502A (zh) * 2020-12-25 2022-07-01 由理生物医药（上海）有限公司 作为kras-g12c抑制剂的螺环类化合物
CN114805311A (zh) * 2021-01-21 2022-07-29 苏州亚盛药业有限公司 螺环茚
WO2022240971A2 (en) * 2021-05-11 2022-11-17 1200 Pharma Llc Kras g12d inhibitors and uses thereof
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023086383A1 (en) * 2021-11-09 2023-05-19 1200 Pharma Llc Select kras g12c inhibitors and uses thereof
WO2023099608A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2209775A1 (en) * 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
KR20160076519A (ko) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017201161A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
US20190134056A1 (en) * 2017-03-10 2019-05-09 The Trustees Of The Stevens Institute Of Technolog K-ras mutations and antagonists
US10745385B2 (en) * 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
JP2020521741A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
IL310023A (en) * 2017-06-21 2024-03-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
MX2020012731A (es) * 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
KR102495687B1 (ko) * 2018-08-16 2023-02-07 에프. 호프만-라 로슈 아게 융합 고리 화합물

Also Published As

Publication number Publication date
WO2020236940A1 (en) 2020-11-26
EP3972978A4 (en) 2023-04-26
IL288200A (en) 2022-01-01
KR20220038289A (ko) 2022-03-28
US20220227738A1 (en) 2022-07-21
SG11202112790SA (en) 2021-12-30
CA3141604A1 (en) 2020-11-26
AU2020279253A1 (en) 2021-12-16
JP2022533398A (ja) 2022-07-22
CN114096544A (zh) 2022-02-25
EP3972978A1 (en) 2022-03-30
MX2021014177A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
CL2023000972A1 (es) Inhibidores de ras
BR112019001666A2 (pt) n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1121040T1 (el) Aντιικη θεραπεια
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112019007144B8 (pt) Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112018070859A2 (pt) degradantes da proteína de bet
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
EA201792116A1 (ru) Ингибитор янус-киназы
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BR112022007612A2 (pt) Inibidores de raf quinases
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
CY1121334T1 (el) Αναστολεας κινασης aurora a